Blog
Valuable TargetsAdvanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Dostarlimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Dostarlimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dostarlimab, a antibody targeting PD-1.
Read →
Redalsomatropin alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Redalsomatropin alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Redalsomatropin alfa: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Rifalazil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Rifalazil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Rifalazil: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Cemiplimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Cemiplimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cemiplimab, a antibody targeting PD-1.
Read →
Nofazinlimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Nofazinlimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Nofazinlimab: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Traneurocin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Traneurocin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Traneurocin: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Tiespectus Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Tiespectus Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Tiespectus: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Cadisegliatin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Cadisegliatin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Cadisegliatin: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Xanomeline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Xanomeline Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Xanomeline: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Nivolumab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Nivolumab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nivolumab, a antibody targeting PD-1.
Read →
Nelipepimut S Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Nelipepimut S Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Nelipepimut S: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Bexicaserin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Bexicaserin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Bexicaserin: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →